Fig. 5: EphrinB2 as a biomarker of pediatric AVM: Urinary EphrinB2 distinguishes AVM patients from controls and from patients with other cerebrovascular disease. | Experimental & Molecular Medicine

Fig. 5: EphrinB2 as a biomarker of pediatric AVM: Urinary EphrinB2 distinguishes AVM patients from controls and from patients with other cerebrovascular disease.

From: Dysregulation of the EphrinB2−EphB4 ratio in pediatric cerebral arteriovenous malformations is associated with endothelial cell dysfunction in vitro and functions as a novel noninvasive biomarker in patients

Fig. 5

a Urinary levels of EphrinB2 are capable of distinguishing patients with AVM from healthy matched controls (p < 0.001). The median levels of urinary EphrinB2 were 35.0 pg/µg (IQR 18.4–84.1) for AVM patients and 11.7 pg/µg (IQR 4.4–19.1) for controls. b Regression modeling demonstrated that urinary biomarkers can predict the presence of AVM with high specificity and sensitivity. A urinary EphrinB2 value > 25 pg/μg was seven times more likely to be present in patients with AVM (AUC 0.801, 95% CI) than it was in controls, and this result was independent of age and sex. c Example of the ability of urinary biomarkers to discriminate between different types of CNS vascular disease. By univariate analysis, levels of urinary EphrinB2 could distinguish between patients with AVM and other cerebrovascular disease (moyamoya) (p < 0.001). The median levels of urinary EphrinB2 were 35.0 pg/µg (IQR 18.4–84.1) for AVM patients and 0.0 pg/µg (0.0–17.2) for moyamoya patients. d Results of the regression modeling showed that a urinary EphrinB2 value > 25 pg/μg was five times more likely to indicate AVM presence (AUC 0.852, 95% CI). e ROC analysis of EphrinB2 showed excellent discrimination when used as an independent marker for AVM versus control with 80% accuracy and AVM versus moyamoya with 75% accuracy.

Back to article page